Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey)

被引：17

作者：

Chuah, Yoen-Young ^{[1
,2
,3
]}

Wu, Deng-Chyang ^{[4
,5
]}

Chuah, Seng-Kee ^{[5
,6
,7
]}

Yang, Jyh-Chin ^{[8
]}

Lee, Tzong-Hsi ^{[9
]}

Yeh, Hong-Zen ^{[10
]}

Chen, Chan-Lin ^{[11
]}

Liu, Yu-Hwa ^{[12
]}

Hsu, Ping-I ^{[1
,2
,5
]}

机构：

[1] Kaohsiung Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Kaohsiung, Taiwan

[2] Natl Yang Ming Univ, Kaohsiung, Taiwan

[3] Ping Tung Christian Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Pingtung, Ping Tung Count, Taiwan

[4] Kaohsiung Med Univ Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan

[5] Taiwan Acid Related Dis TARD Study Grp, Kaohsiung, Taiwan

[6] Kaohsiung Chang Gung Mem Hosp, Div Gastroenterol, Dept Internal Med, Kaohsiung, Taiwan

[7] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan

[8] Natl Taiwan Univ Hosp, Div Gastroenterol, Dept Internal Med, Taipei, Taiwan

[9] Far Eastern Mem Hosp, Div Gastroenterol, Dept Internal Med, Taipei, Taiwan

[10] Taichung Vet Gen Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taichung, Taiwan

[11] Hualian Tzu Chi Med Ctr, Hualien, Hualian County, Taiwan

[12] Shin Kong Wu Ho Su Mem Hosp, Div Gastroenterol, Dept Internal Med, Taipei, Taiwan

来源：

HELICOBACTER | 2017年 / 22卷 / 03期

关键词：

expectation; Helicobacter pylori eradication; real-world practice; STANDARD TRIPLE THERAPY; PROTON PUMP INHIBITOR; 10-DAY SEQUENTIAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; COMPETITIVE ACID BLOCKER; CONCOMITANT THERAPY; CONSENSUS REPORT; HYBRID THERAPY; GASTRIC-CANCER; A-MULTICENTER;

D O I：

10.1111/hel.12380

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

ObjectiveThe aims of the study were: 1, to survey the most popular anti-H.pylori regimens in Asia-Pacific region and the real-world effectiveness of these regimens; and 2, to investigate the expectation gaps of eradication rate between physicians and patients. DesignA questionnaire was distributed to Asia-Pacific physicians who attended the Asia-Pacific Digestive Week 2015 meeting. Reported eradication rates from the literatures were compared with real-world rates of surveyed popular regimens within the region. In addition, a questionnaire was distributed to H.pylori-infected patients in three regions of Taiwan. ResultsA total of 691 physicians and 539 patients participated in the survey. The top five most commonly used regimens were 7-day clarithromycin-based standard triple therapy (50.4%), 14-day clarithromycin-based standard triple therapy (31.0%), 10-day sequential therapy (6.1%), 14-day bismuth quadruple therapy (3.9%), and 14-day hybrid therapy (3.6%). All countries except for China had a significant gap between the expectation of physicians on anti-H.pylori therapy and the real-world eradication rate of most commonly adopted regimens (all P value <.05). The expectation on minimal eradication rate among patients was higher than that of physicians (91.4% vs 86.5%, P<.001). ConclusionsIt is time for physicians in Asia-Pacific countries to adopt newer and more efficacious anti-H.pylori regimens to meet the Kyoto consensus recommendation and their patients' expectations.

引用

页数：9

共 47 条

[1] A new approach for elimination of gastric cancer deaths in Japan [J].